Haleon PLC ( (GB:HLN) ) has provided an announcement.
Haleon PLC announced that as of March 31, 2025, the total number of shares issued is 9,038,156,791, with 4,080,205 held as treasury shares. The number of ordinary shares with voting rights is 9,034,076,586, which shareholders should use as the denominator for determining notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements. Its well-known brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
YTD Price Performance: 3.68%
Average Trading Volume: 27,678,352
Technical Sentiment Signal: Sell
Current Market Cap: £35.23B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.